All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

An expert panel hosted by

The Lymphoma Hub logo and the Multiple Myeloma Hub logo

Sequencing immune-based therapies in B-cell malignancies

with Ulric Jäger, Sagar Lonial, and Krina Patel

Saturday, June 15 | 18:00-19:30 CEST

Register now

This independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.

  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2021-04-20T08:37:38.000Z

EC approves isatuximab combined with carfilzomib and dexamethasone for the treatment of relapsed MM

Apr 20, 2021
Share:

Bookmark this article

On April 19, 2021, it was announced that the European Commission (EC) approved the use of isatuximab (Isa) in combination with carfilzomib and dexamethasone (Kd) for the treatment of adult patients with relapsed multiple myeloma (MM) who have had ≥1 prior therapy. This approval was based on the results of the phase III IKEMA trial (NCT03275285), which were previously reported on the Multiple Myeloma Hub. They showed a 47% reduction in the risk of disease progression or death with Isa-Kd compared with Kd alone (HR, 0.531; 99% CI, 0.318–0.889; p = 0.0007).1

This Isa-Kd combination recently received approval from the U.S. Food and Drug Administration (FDA) for a similar indication, given on March 31, 2021.

  1. Sanofi.European Commission approves second indication of Sarclisa® (isatuximab) for relapsed multiple myeloma. https://www.sanofi.com/en/media-room/press-releases/2021/2021-04-19-07-00-00-2212005. Published Apr 19, 2021. Accessed Apr 19, 2021.

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox